COVID-19
Conditions
Keywords
Coronavirus Disease, Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2
Brief summary
The purpose of the study is to determine if high dose Intravenous IVIG plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day 29 or who are dependent on high flow oxygen devices or invasive mechanical ventilation on Day 29 versus SMT alone in hospitalized participants with COVID-19.
Interventions
BIOLOGICALIntravenous Immune Globulin
IVIG Intravenous infusion
DRUGStandard Medical Treatment
SMT
Sponsors
Instituto Grifols, S.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Hospitalized male or female subject ≥ 18 years of age at time of Screening who is being treated for COVID-19. 2. Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by qualitative Polymerase Chain Reaction (PCR) (reverse transcriptase \[RT\]-PCR), or other commercial or public health assay (of any type) in any specimen during the current hospital admission prior to randomization. 3. COVID-19 illness (symptoms) of any duration with radiographic infiltrates by imaging (Chest X-Ray, Computed tomography (CT) scan, etc.). 4. PaO2/FIO2 ratio \> 300 to ≤ 450 mmHg (i.e., arterial oxygen in mmHg divided by fraction inspired oxygen concentration \[e.g., 0.21 for room air\]) 5. Any one of the following related to COVID-19: i. Ferritin \> 400 nanogram per milliliter (ng/mL), ii. Lactate dehydrogenase (LDH) \> 300 units per liter U/L, iii. D-Dimers \> reference range, or iv. C-reactive protein (CRP) \> 40 milligram per liter (mg/L). 6. Subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides oral informed consent prior to initiation of any study procedures.
Exclusion criteria
1. Subject requires invasive mechanical ventilation or ICU admission. 2. Clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator may place the subject at undue medical risk. 3. The subject has had a known (documented) serious anaphylactic reaction to blood, any blood-derived or plasma product or commercial immunoglobulin. 4. Subject has known (documented) hereditary fructose intolerance (HFI). 5. A medical condition in which the infusion of additional fluid is contraindicated. 6. Shock that is unresponsive to fluid challenge and/or multiple vasopressors and accompanied by multiorgan failure considered by the Principal Investigator not able to be reversed. 7. Subject with known (documented) thrombotic complications to polyclonal IVIG therapy in the past. 8. Subject with current or prior (within the past 1 month) myocardial infarction, stroke, deep vein thrombosis, or thromboembolic event. 9. Subject with limitations of therapeutic effort (eg, 'do not resuscitate' status). 10. Female subject who are pregnant or of child-bearing potential with a positive test for pregnancy blood or urine human chorionic gonadotropin (HCG)-based assay at Screening/Baseline. 11. Subject participating in another interventional clinical trial with investigational medical product or device.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants Dying or Requiring ICU Admission | Up to Day 29 |
| Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation | Day 29 |
Secondary
| Measure | Time frame |
|---|---|
| Time to Hospital Discharge | Day 1 through Day 29 |
| Duration of ICU Stay | Up to Day 29 |
| Duration of Any Oxygen Use | Day 1 through Day 29 |
| Duration of Mechanical Ventilation | Up to Day 29 |
| Mean Change from Baseline in Ordinal Scale | Day 1 through Day 29 |
| Change from Baseline in National Early Warning Score (NEWS) | Day 1 through Day 29 |
| Length of Time to Clinical Progression | Up to Day 29 |
| Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale | Day 15 and Day 29 |
| Time to Sustained Normalization of Temperature | Day 1 through Day 29 |
| Percentage of Participants with Normalization of Fever | Day 1 through Day 29 |
| Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS) | Day 29 |
| Absolute Value Change from Baseline in Ordinal Scale | Day 1 through Day 29 |
| Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours | Day 1 through Day 29 |
Countries
Spain
Outcome results
None listed